A recent study reported that 5-aminosalicylic acid (5-ASA), a PPARγ agonist widely used as a first-line medication for the treatment of ulcerative colitis [27], has been shown to increase mitochondrial respiratory capacity in Caco-2 cells, which was indicative of increased mitochondrial bioenergetics [14]. Here, PPARG is linked to ulcerative colitis.